公开(公告)号：US08357653B2

公开(公告)日：2013-01-22

申请号：US12717470

申请日：2010-03-04

申请人： Nathan C. Maier ,  Amiel G. Jarstfer

发明人： Nathan C. Maier ,  Amiel G. Jarstfer

IPC分类号： A61K38/08 ,  A61P17/12

CPC分类号： A61K38/046

摘要： Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

摘要翻译： 描述了系统和方法，其提供速激肽的治疗制剂，更具体地说是用于治疗与患者身体相关的组织区域中的各种类型的异常细胞增殖病症的治疗制剂。 唾液酸可以从天然或生物工程化来源分离和纯化，或者可以合成，并且可以与植入物组合成植入物，用于局部洗脱或以其它方式混合在用于注射递送的载体载体中的粉末。 肿瘤，疣和再狭窄是通过治疗剂量的sialokinin治疗的异常细胞增殖条件。 要处理的组织结构的大小用于确定sialokinin的治疗剂量。 可以以治疗剂量局部或全身递送sialokinin以获得所需效果。 诸如支架的植入物涂覆有唾液酸溶蛋白，以在损伤或组织的部位进行局部洗脱，否则易受由sialokinin处理的有害条件的影响。

公开(公告)号：US07425217B2

公开(公告)日：2008-09-16

申请号：US10445400

申请日：2003-05-24

申请人： Nathan C. Maier ,  Amiel G. Jarstfer ,  James C. Peacock, III

发明人： Nathan C. Maier ,  Amiel G. Jarstfer ,  James C. Peacock, III

IPC分类号： A61F2/06 ,  A61K39/00 ,  A61K38/00

CPC分类号： A61K38/046

摘要： Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

摘要翻译： 描述了系统和方法，其提供速激肽的治疗制剂，更具体地说是用于治疗与患者身体相关的组织区域中的各种类型的异常细胞增殖病症的治疗制剂。 唾液酸可以从天然或生物工程化来源分离和纯化，或者可以合成，并且可以与植入物组合成植入物，用于局部洗脱或以其它方式混合在用于注射递送的载体载体中的粉末。 肿瘤，疣和再狭窄是通过治疗剂量的sialokinin治疗的异常细胞增殖条件。 要处理的组织结构的大小用于确定sialokinin的治疗剂量。 可以以治疗剂量局部或全身递送sialokinin以获得所需效果。 诸如支架的植入物涂覆有唾液酸溶蛋白，以在损伤或组织的部位进行局部洗脱，否则易受由sialokinin处理的有害条件的影响。

公开(公告)号：US20100228184A1

公开(公告)日：2010-09-09

申请号：US12554758

申请日：2009-09-04

申请人： Akshay MAVANI ,  Kenton FONG ,  Leif E. BANSNER ,  Nathan C. MAIER ,  Dean HU ,  Moshe PINTO ,  Harold F. CARRISON ,  Eliot KIM

发明人： Akshay MAVANI ,  Kenton FONG ,  Leif E. BANSNER ,  Nathan C. MAIER ,  Dean HU ,  Moshe PINTO ,  Harold F. CARRISON ,  Eliot KIM

IPC分类号： A61M1/00 ,  A61M29/00

CPC分类号： A61B17/0057 ,  A61B2017/00004 ,  A61B2017/00579 ,  A61B2017/00588 ,  A61B2017/00592 ,  A61B2017/00597 ,  A61B2017/00601 ,  A61B2017/00606 ,  A61B2017/0061 ,  A61B2017/00623 ,  A61B2017/00641 ,  A61B2017/0065 ,  A61B2017/00898 ,  A61B2017/00902

摘要： Disclosed herein is an implantable fistula closure device. The device may include an expandable longitudinally segmented body including a proximal end and a distal end. The segmented body may further include a plurality of porous bodies and a connecting member operably joining together the plurality of porous bodies. The plurality of porous bodies includes a first porous body with a proximal end and a distal end and a second porous body with a proximal end and a distal end, and the connecting member operably connects the proximal end of the first porous body with the distal end of the second porous body.

摘要翻译： 本文公开了一种植入式瘘闭合装置。 该装置可以包括可扩展的纵向分段的主体，其包括近端和远端。 分段体还可以包括多个多孔体和可操作地将多个多孔体连接在一起的连接构件。 多个多孔体包括具有近端和远端的第一多孔体和具有近端和远端的第二多孔体，并且连接构件将第一多孔体的近端与远端 的第二多孔体。

公开(公告)号：US20110009334A1

公开(公告)日：2011-01-13

申请号：US12717470

申请日：2010-03-04

申请人： Nathan C. Maier ,  Amiel G. Jarstfer

发明人： Nathan C. Maier ,  Amiel G. Jarstfer

IPC分类号： A61K38/08 ,  A61P17/12

CPC分类号： A61K38/046

摘要： Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

摘要翻译： 描述了系统和方法，其提供速激肽的治疗制剂，更具体地说是用于治疗与患者身体相关的组织区域中的各种类型的异常细胞增殖病症的治疗制剂。 唾液酸可以从天然或生物工程化来源分离和纯化，或者可以合成，并且可以与植入物组合成植入物，用于局部洗脱或以其它方式混合在用于注射递送的载体载体中的粉末。 肿瘤，疣和再狭窄是通过治疗剂量的sialokinin治疗的异常细胞增殖条件。 要处理的组织结构的大小用于确定sialokinin的治疗剂量。 可以以治疗剂量局部或全身递送sialokinin以获得所需效果。 诸如支架的植入物涂覆有唾液酸溶蛋白，以在损伤或组织的部位进行局部洗脱，否则易受由sialokinin处理的有害条件的影响。

公开(公告)号：US07691817B2

公开(公告)日：2010-04-06

申请号：US10994170

申请日：2004-11-19

申请人： Nathan C. Maier ,  Amiel G. Jarstfer

发明人： Nathan C. Maier ,  Amiel G. Jarstfer

IPC分类号： A61K38/00

CPC分类号： A61K38/046

摘要： Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.

摘要翻译： 描述了系统和方法，其提供速激肽的治疗制剂，更具体地说是用于治疗与患者身体相关的组织区域中的各种类型的异常细胞增殖病症的治疗制剂。 唾液酸可以从天然或生物工程化来源分离和纯化，或者可以合成，并且可以与植入物组合成植入物，用于局部洗脱或以其它方式混合在用于注射递送的载体载体中的粉末。 肿瘤，疣和再狭窄是通过治疗剂量的sialokinin治疗的异常细胞增殖条件。 要处理的组织结构的大小用于确定sialokinin的治疗剂量。 可以以治疗剂量局部或全身递送sialokinin以获得所需效果。 诸如支架的植入物涂覆有唾液酸溶蛋白，以在损伤或组织的部位进行局部洗脱，否则易受由sialokinin处理的有害条件的影响。

公开(公告)号：US20120016412A1

公开(公告)日：2012-01-19

申请号：US13245748

申请日：2011-09-26

申请人： Akshay MAVANI ,  Kenton Fong ,  Leif E. Bansner ,  Nathan C. Maier ,  Dean Hu ,  Moshe Pinto ,  Harold F. Carrison ,  Eliot Kim

发明人： Akshay MAVANI ,  Kenton Fong ,  Leif E. Bansner ,  Nathan C. Maier ,  Dean Hu ,  Moshe Pinto ,  Harold F. Carrison ,  Eliot Kim

IPC分类号： A61B17/03

CPC分类号： A61B17/0057 ,  A61B2017/00004 ,  A61B2017/00579 ,  A61B2017/00588 ,  A61B2017/00592 ,  A61B2017/00597 ,  A61B2017/00601 ,  A61B2017/00606 ,  A61B2017/0061 ,  A61B2017/00623 ,  A61B2017/00641 ,  A61B2017/0065 ,  A61B2017/00898 ,  A61B2017/00902

摘要： Disclosed herein is an implantable fistula closure device. The device may include an expandable longitudinally segmented body including a proximal end and a distal end. The segmented body may further include a plurality of porous bodies and a connecting member operably joining together the plurality of porous bodies. The plurality of porous bodies includes a first porous body with a proximal end and a distal end and a second porous body with a proximal end and a distal end, and the connecting member operably connects the proximal end of the first porous body with the distal end of the second porous body.

摘要翻译： 本文公开了一种植入式瘘闭合装置。 该装置可以包括可扩展的纵向分段的主体，其包括近端和远端。 分段体还可以包括多个多孔体和可操作地将多个多孔体连接在一起的连接构件。 多个多孔体包括具有近端和远端的第一多孔体和具有近端和远端的第二多孔体，并且连接构件将第一多孔体的近端与远端 的第二多孔体。